Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

@article{Keystone2008CertolizumabPP,
  title={Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.},
  author={Edward Clark Keystone and D{\'e}sir{\'e}e van der Heijde and David Mason and Robert B. M. Landew{\'e} and Ronald F. van Vollenhoven and Bernard G Combe and Paul Emery and Vibeke Strand and Philip J Mease and Chintu Desai and Karel Pavelka},
  journal={Arthritis and rheumatism},
  year={2008},
  volume={58 11},
  pages={3319-29}
}
OBJECTIVE To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab pegol (a novel PEGylated anti-tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with an inadequate response to MTX therapy alone. METHODS In this 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, 982 patients were randomized 2:2:1 to receive treatment with subcutaneous… CONTINUE READING
Highly Influential
This paper has highly influenced 26 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS